A novel replicase-mediated self-amplifying RNA amplification mechanism of the SARS-CoV-2 replication-transcription system.

Publication date: Mar 18, 2025

A novel self-amplifying mRNA (samRNA) amplification mechanism was first discovered in the SARS-CoV-2 replication-transcription system and named replicase cycling reaction (RCR). In principle, RCR is a replicase-mediated transcription reaction driven by the SARS-CoV-2 RNA-dependent RNA polymerases (RdRPs), which amplify a specific samRNA construct consisting of an RNA/mRNA sequence flanked by a 5′-end RdRP-reverse-promoter (5′-RdRP-RP) and a 3′-end RdRP-forward-promoter (3′-RdRP-FP) on both sides. Based on this samRNA composition, we had not only successfully established the first in-vitro RCR reaction for directly amplifying the SARS-CoV-2 genomic and subgenomic RNAs but also further used it in a combined in-vitro-transcription and RCR (IVT-RCR) protocol to identify new functions of the SARS-CoV-2 NSP7, NSP8, and NSP12 proteins, leading to a fast diagnostic assay for measuring the SARS-CoV-2 RdRP activity. These findings may shed a new light on the molecular mechanisms of SARS-CoV-2 replication and transcription. As a result, in addition to the previously found primer-dependent RNA synthesis activity of the coronaviral RdRP complexes, we herein reported another new 5’/3′-promoter-dependent, primer-independent samRNA synthesis mechanism mediated by the SARS-CoV-2 RdRP complex. Based on this novel RCR mechanism, the associated samRNA composition is conceivably useful for facilitating the design and development of next-generation RNA/mRNA medicines and vaccines.

Open Access PDF

Concepts Keywords
Biochem mRNA vaccine
Fast RNA medicine
Mrna SARS-CoV-2
Promoter Self-amplifying mRNA (samRNA)
Vaccines

Semantics

Type Source Name
disease IDO replication
disease IDO assay
drug DRUGBANK Ademetionine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH COVID 19 pandemic
disease IDO production
disease IDO host
disease IDO cell
drug DRUGBANK Coenzyme M
disease IDO protein
disease MESH alveolar adenocarcinoma
disease IDO reagent
drug DRUGBANK Tretamine
drug DRUGBANK Tromethamine
drug DRUGBANK Spermidine
disease MESH Vaccinia
drug DRUGBANK Formaldehyde
drug DRUGBANK 2′-Deoxycytidine 5′-triphosphate
drug DRUGBANK Sodium lauryl sulfate
disease MESH SSPE
pathway KEGG Ribosome
drug DRUGBANK Hyaluronic acid
pathway REACTOME Digestion
drug DRUGBANK Spinosad
disease MESH infectious diseases
disease MESH tumors
disease MESH Ebola virus infection
disease MESH Middle East respiratory syndrome
drug DRUGBANK Carboxyamidotriazole
pathway KEGG Virion
drug DRUGBANK L-Leucine

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *